VivoSeq
Other

Lung Transplantation

49

Pipeline Programs↗

3

Active Trials↗

19

Companies Involved↗

Lung Transplantation is a moderately active landscape with 49 programs across 19 companies. The most active players are Eli Lilly, RECORDATI GROUP, Pfizer. 17 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

11/100

Mech. Concentration

14/100

Completion Rate

76/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 1R

RECORDATI GROUP

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

49 of 54 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody36%Protein / enzyme12%Vaccine12%

Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 98% of 58 pipeline programs.

Analysis

Trial Status

47

clinical trials

Completed28 · 60%
Unknown status7 · 15%
Terminated6 · 13%
Withdrawn3 · 6%
Recruiting2 · 4%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

47 trials

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
Recruiting·WWashington University School of Medicine·Phase 1·NCT06990711·30 enrolled
Tocilizumab in Lung Transplantation
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06033196·350 enrolled
Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies.
Not yet recruiting·National Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT06948097·30 enrolled
Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation
Completed·WWashington University School of Medicine·Phase 2·NCT03388008·27 enrolled
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Completed·—·Phase 3·NCT00227370·136 enrolled
A Comparison of Propofol Based Total Intravenous Anesthesia and Sevoflurane Based Balanced Anesthesia on Renal Protection During Lung Transplantation Under Extracorporeal Membrane Oxygenation - A Prospective, Randomized Trial
Completed·YYonsei University·Phase 4·NCT02009280·60 enrolled
Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation
Completed·KKU Leuven·Phase 4·NCT01109160·15 enrolled
Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation
Completed·AApeptico Forschung und Entwicklung GmbH·Phase 2·NCT02095626·20 enrolled
Expanding the Pool in Lung Transplantation
Completed·—·Phase 1·NCT03377478·10 enrolled
Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement
Completed·UUniversity of Pittsburgh·N/A·NCT01361178·133 enrolled
Imaging and Understanding BOS in Lung Transplantation
Completed·—·N/A·NCT02316392·6 enrolled
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
Completed·—·Phase 2·NCT00224406·114 enrolled
Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
Completed·—·Phase 2·NCT02474927·22 enrolled
Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation
Completed·HHannover Medical School·Phase 3·NCT00402532·190 enrolled
Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation
Completed·UUniversity of Colorado, Denver·Phase 1·NCT01916577·15 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)